ENALAPRIL AFTER ANTHRACYCLINE CARDIOTOXICITY

这项随机、双盲安慰剂对照试验的主要目的是确定长期服用依那普利（一种血管紧张素转换酶抑制剂）是否会降低无明显充血性心力衰竭患者蒽环类药物引起的心功能障碍的发生率。所有的患者必须有记录的心脏异常继发于用于治疗儿童恶性肿瘤的人环类药物，并已接受治疗超过两年。

The primary objective of this randomized, double-blinded placebo controlled trial is to determine whether the long-term administration of enalapril, an angiotensin converting enzyme inhibitor, will decrease the rate of anthracycline-induced cardiac dysfunction in patients without overt congestive heart failure. All patients must have documented cardiac abnormalities secondary to anthrocyclines used for treating pediatric malignancies and have received therapy more than two years ago.